278 related articles for article (PubMed ID: 7514563)
21. [Decarboxyprothrombin: importance in the diagnosis of hepatocellular carcinoma].
Bon C; Brillard B; Gelineau MC; Mailliavin A; Trépo C; Pichot J
Ann Biol Clin (Paris); 1998; 56(2):175-81. PubMed ID: 9754243
[TBL] [Abstract][Full Text] [Related]
22. Significance of alpha-fetoprotein and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomy.
Yamamoto K; Imamura H; Matsuyama Y; Hasegawa K; Beck Y; Sugawara Y; Makuuchi M; Kokudo N
Ann Surg Oncol; 2009 Oct; 16(10):2795-804. PubMed ID: 19669841
[TBL] [Abstract][Full Text] [Related]
23. Sensitivity and specificity of des-gamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size.
Nakamura S; Nouso K; Sakaguchi K; Ito YM; Ohashi Y; Kobayashi Y; Toshikuni N; Tanaka H; Miyake Y; Matsumoto E; Shiratori Y
Am J Gastroenterol; 2006 Sep; 101(9):2038-43. PubMed ID: 16848811
[TBL] [Abstract][Full Text] [Related]
24. Serum des-gamma-carboxy prothrombin levels determined by a new generation of sensitive immunoassays in patients with small-sized hepatocellular carcinoma.
Nomura F; Ishijima M; Kuwa K; Tanaka N; Nakai T; Ohnishi K
Am J Gastroenterol; 1999 Mar; 94(3):650-4. PubMed ID: 10086646
[TBL] [Abstract][Full Text] [Related]
25. Development of a novel assay to quantify serum human telomerase reverse transcriptase messenger RNA and its significance as a tumor marker for hepatocellular carcinoma.
Miura N; Maruyama S; Oyama K; Horie Y; Kohno M; Noma E; Sakaguchi S; Nagashima M; Kudo M; Kishimoto Y; Kawasaki H; Hasegawa J; Shiota G
Oncology; 2007; 72 Suppl 1():45-51. PubMed ID: 18087181
[TBL] [Abstract][Full Text] [Related]
26. Simultaneous measurements of serum alpha-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma. South Tohoku District Study Group.
Ishii M; Gama H; Chida N; Ueno Y; Shinzawa H; Takagi T; Toyota T; Takahashi T; Kasukawa R
Am J Gastroenterol; 2000 Apr; 95(4):1036-40. PubMed ID: 10763956
[TBL] [Abstract][Full Text] [Related]
27. Serial changes in serum alpha-fetoprotein prior to detection of hepatocellular carcinoma in liver cirrhosis.
Kuwahara T; Sakai T; Majima Y; Hirai K; Tanikawa K
Hepatogastroenterology; 1993 Aug; 40(4):347-51. PubMed ID: 7691701
[TBL] [Abstract][Full Text] [Related]
28. [Serum arginase activity in patients with liver cirrhosis and hepatocellular carcinoma].
Chrzanowska A; Mielczarek-Puta M; Skwarek A; Krawczyk M; Barańczyk-Kuźma A
Wiad Lek; 2007; 60(5-6):215-8. PubMed ID: 17966882
[TBL] [Abstract][Full Text] [Related]
29. [Screening for hepatocellular carcinoma].
Leone N; Rizzetto M
Minerva Med; 2005 Apr; 96(2):95-108. PubMed ID: 16172579
[TBL] [Abstract][Full Text] [Related]
30. [A preliminary study on serum alpha-L-fucosidase assay in the diagnosis of hepatocellular carcinoma].
Shen W; Shen DM
Zhonghua Nei Ke Za Zhi; 1989 Jul; 28(7):397-9, 442-3. PubMed ID: 2480210
[TBL] [Abstract][Full Text] [Related]
31. Tumour-specific induction of immune complexes: DCP-IgM in hepatocellular carcinoma.
Beneduce L; Pesce G; Gallotta A; Zampieri F; Biasiolo A; Tono N; Boscato N; Gatta A; Pontisso P; Fassina G
Eur J Clin Invest; 2008 Aug; 38(8):571-7. PubMed ID: 18625005
[TBL] [Abstract][Full Text] [Related]
32. Elevation of serum type IV collagen in liver cancer as well as liver cirrhosis.
Hong WS; Hong SI; Park SY; Son Y; Lee YS; Chung YH; Yang SK; Suh DJ; Min YI
Anticancer Res; 1995; 15(6B):2777-80. PubMed ID: 8669863
[TBL] [Abstract][Full Text] [Related]
33. Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma.
Oka H; Tamori A; Kuroki T; Kobayashi K; Yamamoto S
Hepatology; 1994 Jan; 19(1):61-6. PubMed ID: 7506227
[TBL] [Abstract][Full Text] [Related]
34. Clinical characteristics among patients with hepatocellular carcinoma according to the serum levels of alpha-fetoprotein and des-y-carboxy prothrombin.
Dohmen K; Shigematsu H; Irie K; Ishibashi H
Hepatogastroenterology; 2003; 50(54):2072-8. PubMed ID: 14696467
[TBL] [Abstract][Full Text] [Related]
35. [Evaluation of diagnostic performance of alpha-fetoprotein (AFP) and des-gamma-carboxy prothrombin (DCP) for HCV related hepatocellular carcinoma developed after long-term follow up].
Ishida H; Matsuo S; Inoue Y
Rinsho Byori; 2010 Nov; 58(11):1065-72. PubMed ID: 21229703
[TBL] [Abstract][Full Text] [Related]
36. The clinical significance of serum alpha-L-fucosidase assay in hepatocellular carcinoma.
Yamamoto K; Yanagita T; Watanabe N; Morito F; Ozaki I; Motomura M; Ikuyama S; Setoguchi Y; Fujii S; Kariya T
Fukuoka Igaku Zasshi; 1988 Jun; 79(6):463-8. PubMed ID: 2852632
[No Abstract] [Full Text] [Related]
37. [Des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma].
Yamashiki M; Kosaka Y
Rinsho Byori; 1989 Feb; 37(2):118-21. PubMed ID: 2471846
[No Abstract] [Full Text] [Related]
38. Use of serum PIVKA-II (DCP) determination for differentiation between benign and malignant liver diseases.
Lamerz R; Runge M; Stieber P; Meissner E
Anticancer Res; 1999; 19(4A):2489-93. PubMed ID: 10470180
[TBL] [Abstract][Full Text] [Related]
39. Alpha-L-fucosidase as a tumour marker of hepatocellular carcinoma.
Fawzy Montaser M; Amin Sakr M; Omar Khalifa M
Arab J Gastroenterol; 2012 Mar; 13(1):9-13. PubMed ID: 22560818
[TBL] [Abstract][Full Text] [Related]
40. Screening for hepatocellular carcinoma.
Haydon GH; Hayes PC
Eur J Gastroenterol Hepatol; 1996 Sep; 8(9):856-60. PubMed ID: 8889450
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
